Linagliptin Sandoz

Linagliptin, the active ingredient in Linagliptin Sandoz, is a DPP-4 inhibitor presented as an oral tablet for oral use. It is prescribed to improve glycaemic control in adults with type 2 diabetes mellitus, often in combination with diet, exercise and other antidiabetic agents.

GNH USA supplies Linagliptin Sandoz as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand, including temperature‑controlled logistics where required.

Linagliptin is a DPP-4 inhibitor used in the management of type 2 diabetes mellitus.

- Type 2 diabetes mellitus (monotherapy): lowers blood glucose when used alone. - Type 2 diabetes mellitus (add‑on to metformin): enhances glycaemic control when combined with metformin. - Type 2 diabetes mellitus (add‑on to insulin): improves post‑prandial glucose when combined with insulin therapy.

Adverse reactions reported with linagliptin vary in frequency and severity.

Common Side Effects: - Nasopharyngitis: mild upper‑respiratory tract infection. - Headache: transient mild to moderate pain. - Dizziness: occasional light‑headedness. - Gastrointestinal upset: nausea or abdominal discomfort. - Back pain: intermittent musculoskeletal discomfort. - Arthralgia: joint pain without swelling.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Hepatic injury: elevated liver enzymes or jaundice. - Hypoglycaemia (when combined with insulin or sulfonylureas): low blood sugar episodes. - Bullous skin reactions: blistering skin conditions such as Stevens‑Johnson syndrome. - Severe cutaneous adverse reactions: toxic epidermal necrolysis.

When prescribing linagliptin, clinicians should consider the following precautions.

- Renal impairment: monitor renal function; dose adjustment is not required but caution is advised. - Hepatic impairment: use with caution and monitor liver enzymes regularly. - Risk of hypoglycaemia: avoid or adjust concomitant insulin or sulfonylurea therapy. - Pregnancy and lactation: safety not established; use only if benefits outweigh potential risks. - Elderly patients: monitor for adverse reactions due to possible comorbidities. - Store at ambient temperature: keep below 25 °C, retain in the original packaging, and protect from moisture.

Linagliptin may interact with other medicines; awareness of the interaction level helps guide clinical decisions.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase linagliptin exposure. - Concomitant insulin or sulfonylureas: heightened risk of hypoglycaemia. - Drugs known to cause pancreatitis: additive risk of pancreatic inflammation.

Moderate Interactions (Monitor Closely):\n- Rifampin: may reduce linagliptin plasma concentrations. - Diuretics: monitor blood glucose as fluid shifts can affect glycaemic control. - ACE inhibitors: no significant interaction but renal function should be monitored.